For a better experience of our website please update you web browser from IE11 to Microsoft Edge or an alternative modern browser such as Google Chrome. Thank you.
Delivering the Added Dimension in Drug Discovery Services
Chemistry Innovation Research Centre
A state of the art digitally enabled chemistry research facility with more than 200,000 sqft lab space. Designed for speed and efficiency with Covid-19 measures built in for maximum safety.
Delivering the Added Dimension in Drug Discovery
Time is a defining factor in drug discovery today. Our people, systems and processes are honed for delivering the highest quality results to enable our innovator customers to accelerate drug discovery for final IND submission.
Deep & Defining Scientific Know-how
Employing dedicated scientists with over 14 years experience in oncology, metabolic disorders, CNS, pain, inflammation and fibrosis as well as multiple niche therapeutic areas.
Delivering over 75 Integrated Discovery Projects
Our track record of achieving results is our platform for the future. Customers can choose individual functional services or a fully integrated solution.
Diligent Quality through our Team Approach
A focus on quality and utilizing our highly qualified scientists is part of our ongoing process. The attention to detail needed at every stage from communication to implementation is built into our services.
Developing your Drug Candidate
We rapidly scale-up your candidate for GLP TOX and GMP Phase 1 or 2 fully integrated with our PR&D and Analytical Teams. This saves valuable time to achieve your milestones.
Jubilant Biosys - Contract Research Organisation in India
Jubilant Biosys Ltd is a part of the Jubilant Life Sciences family of companies with R&D centers in India and business offices in Asia and North America. With our global reach, Jubilant Biosys provides comprehensive drug discovery services and contract research services - from target discovery to candidate selection and with flexible business models (FFS, FTE and risk shared) - in partnership with leading worldwide healthcare.
Measures to curb the spread of novel Coronavirus (COVID-19)
Given the ongoing threat by the novel Coronavirus (COVID-19), Jubilant Life Sciences Limited has taken several measures to curb the spread of the contagious virus among its employees and stakeholders. Click here to read the full statement